ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

NCT05446298 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
High Grade Serous Adenocarcinoma of Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions

DRUG: ONC-392
DRUG: Pembrolizumab

Sponsor

OncoC4, Inc.

Collaborators

[object Object]
[object Object]